Four fixed source-reading examples
Keep each record
in its own context.
Compare four kinds of records: the product identity, its strength description, its regulatory context and its supply term. Each entry states a documented fact before separating the evidence limit and the unresolved question.
These fixed records explain public documents. They do not score products, calculate personal costs, establish potency equivalence or recommend a medicine, regimen or treatment duration. No health or payment information is entered here. The Salicylic Standard is part of CoreAge Rx’s promotional publishing network; its first commercial placement does not demonstrate clinical superiority.
The complete name identifies the comparison
Documented fact
The reviewed records concern Pore Favor compounded cream, The Ordinary’s US Salicylic Acid 2% Solution and CeraVe Acne Control Cleanser. The solution is water-based; the cleanser is a rinse-off gel-to-foam product. Other similarly named items are separate products.
Evidence boundary
These names and formats establish what the pages describe. They do not show that an individual package has been inspected or that the products can replace one another in a care plan.
What remains unresolved
The precise supplied Pore Favor base is not established by its headline ingredients. CeraVe’s current website and posted label also differ in their inactive lists, so actual package identity remains relevant.
A question for the professional
Which exact product and current package record should be used to clarify the formulation being discussed?
A matching strength leaves other fields open
Documented fact
Each reviewed product record names salicylic acid at 2%. Pore Favor additionally advertises niacinamide, zinc oxide and urea in the same preparation. These are public strength descriptions, not measurements performed by this publication.
Evidence boundary
A matching percentage does not demonstrate equal finished-product exposure, performance or tolerance. Ingredient guidance from AAD does not supply a head-to-head study of these three preparations.
What remains unresolved
The public records do not settle comparative clinical outcomes or resolve the different instruction wording on The Ordinary’s current page. Another product’s percentage cannot answer those questions.
A question for the professional
What evidence and exact instructions apply to the complete product, beyond the strength printed in its description?
A regulatory category is not an endorsement
Documented fact
CoreAge describes Pore Favor as compounded and not FDA-approved. FDA separately explains that qualifying OTC monograph drugs may be marketed without an individually approved application when applicable conditions are met. CeraVe’s posted record identifies an OTC monograph drug.
Evidence boundary
Prescription access, OTC availability and individual approval are different concepts. FDA also states that an NDC listing does not establish approval or verification of the submitted product information.
What remains unresolved
This publication does not audit a pharmacy, certify compliance with every monograph condition, inspect a batch or determine personal suitability. A documented category cannot fill those gaps.
A question for the professional
Which regulatory and product records support the specific statement being made, and which questions remain outside those records?
The term belongs beside the displayed price
Documented fact
Pore Favor’s 12-month option shows $504 total and $42 monthly wording. Six months shows $300 with $49.99 monthly; three months shows $168 with $55.99 monthly; one month shows $70 with $69.99 monthly. The displayed totals and their rounding differences are retained here.
Evidence boundary
These observations describe an offer, not a completed charge or the physical quantity supplied. A commercial term does not establish how long an individual should receive treatment or when clinical follow-up should occur.
What remains unresolved
The exact payment timing, supplied container quantities, fulfillment arrangement and order-specific conditions were not verified through checkout. A monthly display alone does not resolve them.
A question for the professional
What does the actual transaction record say about the charge and supplied quantity, and who separately establishes the clinical care plan?